S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)

Freeline Therapeutics (FRLN) Stock Forecast, Price & News

$4.33
+0.42 (+10.74%)
(As of 09/27/2023 ET)
Compare
Today's Range
$3.78
$4.44
50-Day Range
$3.16
$5.10
52-Week Range
$2.11
$12.00
Volume
53,212 shs
Average Volume
167,587 shs
Market Capitalization
$18.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.25

Freeline Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
210.3% Upside
$13.25 Price Target
Short Interest
Healthy
2.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.04) to ($1.20) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

673rd out of 963 stocks

Biological Products, Except Diagnostic Industry

106th out of 159 stocks


FRLN stock logo

About Freeline Therapeutics (NASDAQ:FRLN) Stock

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

FRLN Price History

FRLN Stock News Headlines

The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
4 Analysts Have This to Say About Freeline Therapeutics
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Freeline Therapeutics's Earnings: A Preview
Freeline Therapeutics Holdings plc
Freeline (FRLN) Earnings Dates & Reports
Freeline Completes ADS Ratio Change
See More Headlines
Receive FRLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FRLN Company Calendar

Last Earnings
8/15/2023
Today
9/27/2023
Next Earnings (Estimated)
11/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FRLN
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.25
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+211.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-88,970,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$12.07 per share

Miscellaneous

Free Float
4,259,000
Market Cap
$18.49 million
Optionable
Not Optionable
Beta
0.68
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Michael J. Parini J.D. (Age 48)
    CEO & Exec. Director
    Comp: $2.16M
  • Mr. Paul M. Schneider (Age 52)
    CFO & Director
  • Dr. Henning R. Stennicke Ph.D. (Age 55)
    Chief Scientific Officer
  • Ms. Nicole Jones SPHR (Age 52)
    Chief People Officer
  • Mr. James Bircher (Age 55)
    Chief Technical Operations Officer
  • Dr. Pamela Foulds M.D. (Age 53)
    Chief Medical Officer
  • Ms. Naomi Aoki
    Sr. VP of Corp. Communications & Investor Relations
  • Ms. Amy J. Spandau (Age 48)
    Interim Head of Fin.













FRLN Stock - Frequently Asked Questions

Should I buy or sell Freeline Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FRLN shares.
View FRLN analyst ratings
or view top-rated stocks.

What is Freeline Therapeutics' stock price forecast for 2023?

3 equities research analysts have issued twelve-month price objectives for Freeline Therapeutics' stock. Their FRLN share price forecasts range from $3.00 to $30.00. On average, they anticipate the company's stock price to reach $13.25 in the next year. This suggests a possible upside of 211.0% from the stock's current price.
View analysts price targets for FRLN
or view top-rated stocks among Wall Street analysts.

How have FRLN shares performed in 2023?

Freeline Therapeutics' stock was trading at $7.1265 on January 1st, 2023. Since then, FRLN stock has decreased by 40.2% and is now trading at $4.26.
View the best growth stocks for 2023 here
.

When is Freeline Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our FRLN earnings forecast
.

How were Freeline Therapeutics' earnings last quarter?

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) announced its quarterly earnings data on Tuesday, August, 15th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($3.62) by $3.41. The business earned $0.62 million during the quarter.

When did Freeline Therapeutics' stock split?

Freeline Therapeutics shares reverse split on Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Freeline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE), BigCommerce (BIGC), Checkmate Pharmaceuticals (CMPI), CVS Health (CVS), Old Dominion Freight Line (ODFL), Oak Street Health (OSH), Rocket Companies (RKT), Shopify (SHOP), Zoom Video Communications (ZM) and Zymeworks (ZYME).

When did Freeline Therapeutics IPO?

(FRLN) raised $126 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Freeline Therapeutics' stock symbol?

Freeline Therapeutics trades on the NASDAQ under the ticker symbol "FRLN."

Who are Freeline Therapeutics' major shareholders?

Freeline Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Syncona Portfolio Ltd (33.79%), Renaissance Technologies LLC (0.50%), CHI Advisors LLC (0.50%), Northern Trust Corp (0.36%) and Harbor Capital Advisors Inc. (0.25%).

How do I buy shares of Freeline Therapeutics?

Shares of FRLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Freeline Therapeutics' stock price today?

One share of FRLN stock can currently be purchased for approximately $4.26.

How much money does Freeline Therapeutics make?

Freeline Therapeutics (NASDAQ:FRLN) has a market capitalization of $18.49 million. The company earns $-88,970,000.00 in net income (profit) each year or ($8.3990) on an earnings per share basis.

How many employees does Freeline Therapeutics have?

The company employs 152 workers across the globe.

How can I contact Freeline Therapeutics?

Freeline Therapeutics' mailing address is STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD STEVENAGE, HERTFORDSHIRE X0, SG12FX. The official website for the company is www.freeline.life. The company can be reached via phone at 44-0-14-3890-6870 or via email at ir@freeline.life.

This page (NASDAQ:FRLN) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -